PHAR 441 Lecture Notes - Lecture 5: Avascular Necrosis, Rank, Aromatase

• School: UBC
• Department: Pharmaceutical Sciences
• Course: PHAR 441
• Professor: Arun Verma

Document Summary

Encourage basic bone health for people >50 y/o: Intermediate take a more detailed risk assessment, consider patient preference. A(cid:272)ti(cid:448)atio(cid:374) f(cid:396)e(cid:395)ue(cid:374)(cid:272)(cid:455) of bmu this decreases overall bone turnover. Restores remodeling balance (cid:396)eso(cid:396)ptio(cid:374) (cid:449)ithout affe(cid:272)ti(cid:374)g fo(cid:396)(cid:373)atio(cid:374) (because in osteoporosis, the balance favors bone resorption if not treated) This effect is transient: the bmd will increase rapidly as the current bmu sites fill in. But then the drug just decreases the remodeling process, leading to a plateau in the bmu percent change. (cid:271)o(cid:374)e fo(cid:396)(cid:373)atio(cid:374) in bone remodeling in each bmu. Also might stimulate osteoblasts without needing a preceding resorption phase bone modeling. Estrogen alone or with progestins reduced risk of fractures in postmenopausal women. The long term benefits didn"t outweigh the risks. Raloxifene = a serm (selective estrogen receptor modulator) that doesn"t cause endometrial stimulation it"s a pa(cid:396)tial est(cid:396)oge(cid:374) ago(cid:374)ist. Antagonist in uterus and breast decreases unwanted estrogen effects. Bmd i(cid:374) postmenopausal women, but less than estrogen or alendronate.